With the expected launch of Northwest Biotherapeutics' dendritic cell-based therapeutic vaccine DCVax-L, the glioblastoma multiforme drug market is expected to grow rapidly, from $305 million in 2012 to $583 million in 2019, according to market research.
Johns Hopkins researchers published a study showing they can use biodegradable nanoparticles to carry DNA to brain cancer cells. The animal study suggests that these vehicles could deliver what they call "death genes" to the cells, treating the cancer while preserving healthy brain cells in the process.
A class of FDA-approved antipsychotic drugs may provide a new approach to treating the most aggressive form of primary brain cancer, glioblastoma.
Bethesda, MD's Northwest Biotherapeutics has watched as rivals Dendreon and ImmunoCellular have run into serious roadblocks with personalized cancer vaccines over the past year, but with a major Phase III study underway, the biotech believes it can change the narrative.
The cancer immunotherapy biotech Agenus has continued its march back from a big R&D setback earlier in the year, seeing its share price spike 36% this morning after posting positive results for a single-arm Phase II study of one of its brain cancer vaccines.
An investigative team at the University of Zurich says they have nailed down some clear proof-of-principle evidence in animal studies that a combination of interleukin-12 used in a combo immunotherapy approach offers a promising new avenue of research in tackling lethal cases of brain cancer.
A cellular pathway interaction that plays a role in repairing serious injuries may also be a promising target for preventing the spread of a deadly type of brain cancer, according to a new study.
Using a similar method they once used to treat breast cancer, researchers at UCLA are employing nanodiamonds to deliver cancer drugs to the brain, providing treatment for the particularly aggressive glioblastoma.
A new stem cell treatment that combines neural stem cells with chemo-radiotherapy drugs could provide a better way to combat glioblastoma, the most common and lethal form of adult brain cancer.
An experimental drug being developed by scientists at the Ohio State University Comprehensive Cancer Center can cross the blood-brain barrier, making it a promising novel treatment for deadly brain tumors.